A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This is a First-in-Human phase I study to evaluate the safety, tolerability and
pharmacokinetic characteristics of MAX-40070 in Healthy SubjectThe study will be comprised of
2 parts; Part A and Part B. Part A will be conducted at NZCR, and Part B will be conducted at
both NZCR and another site(s) in China (if required). Part A will include approximately 48
participants, and Part B will include approximately 30 participants.